This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
$1 buys you full access to ALL of TheStreet's Subscription Services! Learn More

Adam Feuerstein

Senior Columnist

Before joining TheStreet in March 2001, Feuerstein covered business software for Upside.com. Prior to that he covered a variety of business beats, including technology and commercial real estate, at the San Francisco Business Times.


Feuerstein graduated from Emory University with a bachelor's degree in political science.


Adam Feuerstein
By This Author:
Page 2 of 577

Celldex Immunotherapy Prolongs Survival for Recurrent Brain Tumor Patients

By Adam Feuerstein

Positive data presented Friday, particularly the statistically significant survival benefit favoring patients treated with rindopepimut, has Celldex planning -- cautiously -- for a conversation with the FDA about accelerated approval.

03:35PM 11/14/14

Biotech Stock Mailbag: Spectrum, Intercept, Orexigen, Amarin, MannKind

By Adam Feuerstein

Biotech columnist Adam Feuerstein answers readers' questions about health care.

06:00AM 11/14/14

Geron Licenses Experimental Myelofibrosis Drug to Johnson & Johnson

By Adam Feuerstein

J&J is paying $35 million upfront to Geron for rights to the drug.

04:34PM 11/13/14

Oxigene Faces Challenges for Ovarian Cancer Drug Even With Encouraging Data

By Adam Feuerstein

An analysis of results from Oxigene's phase II study of fosbretabulin plus Avastin in recurrent ovarian cancer.

05:12AM 11/12/14

Buyside Buzz on Gilead, Regulus From This Year's Liver Meeting

By Adam Feuerstein

Here's a quick sketch of the Wall Street gossip mill emerging from the 'Liver Meeting.'

10:40AM 11/10/14

The Next Chapter in Dendreon's Troubled History: Chapter 11 Bankruptcy

By Adam Feuerstein

A Dendreon agreement calls for a financial restructuring of the company in which the bondholders will receive equity for the debt owed, potentially wiping out current equity shareholders.

07:12AM 11/10/14

Severe Epileptic Patients in Coma Respond to Sage Therapeutics Experimental Drug

By Adam Feuerstein

Based on promising results from a small study, Sage expects to start a larger phase III study of its anti-seizure drug next year.

12:11AM 11/10/14

Merck's Shortened Hep C Regimens Fall Short of Cure-Rate Goal

By Adam Feuerstein

A triple therapy combining two experimental Merck drugs with Gilead's Sovaldi yielded interim hepatitis C cure rates for ranging from 80% to 87% following six to eight weeks of treatment.

06:23PM 11/09/14

Rockwell Dialysis Therapy Wins Panel Support but Final FDA Approval? Not So Fast.

By Adam Feuerstein

A deeply flawed FDA advisory panel voted to support Rockwell's iron replacement therapy for dialysis. FDA still must decide if the product is approvable.

07:44AM 11/07/14

Salix Shares Plummet on Disclosure of Accounting Scandal

By Adam Feuerstein

Salix Pharmaceuticals has been rocked by an accounting scandal involving inventory levels of its key gastrointestinal drugs, forcing the company to cut financial forecasts for the rest of the year.

07:33PM 11/06/14

Page 2 of 577

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV

Markets

DOW 17,873.52 +45.77 0.26%
S&P 500 2,073.16 +0.33 0.02%
NASDAQ 4,806.3840 +19.0670 0.40%

Brokerage Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs